drugset / Trial / NCT07414706
Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery
RandomizedParallel-groupSingle-blindTreatment
Summary
This randomized controlled trial evaluates whether perioperative intravenous lidocaine infusion, combined with port-site ropivacaine infiltration, improves postoperative recovery after laparoscopic abdominal surgery. Participants will be assigned 1:1 to receive either intravenous lidocaine during surgery plus ropivacaine infiltration at surgical closure, or ropivacaine infiltration alone. The primary endpoint is postoperative quality of recovery measured by the QoR-15 questionnaire. Secondary endpoints include postoperative pain and opioid consumption, as well as plasma lidocaine and ropivacaine concentrations to assess systemic exposure and safety.
Timeline
- Start
- 2026-03
- Primary completion
- 2028-06
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lidocaine | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Ropivacaine | Other / unclassified | 2 mg/ml | Other |
| Subject | Ropivacaine | Other / unclassified | 20 ml | Other |
| Background | Acetaminophen | Small molecule | 1 g | — |
| Background | Celecoxib | Other / unclassified | 100 mg | — |
| Background | Dexamethasone | Small molecule | 8 mg | — |
| Background | Ketamine | Small molecule | 0.5 mg/kg | — |
| Background | Morphine | Other / unclassified | — | — |
| Background | Nefopam | Small molecule | 20 mg | — |
| Background | Nefopam | Small molecule | 30 mg | — |
| Background | Parecoxib | Small molecule | 40 mg | — |
| Background | Propofol | Small molecule | 2 mg/kg | — |
| Background | Sufentanil | Other / unclassified | 0.2 ug/kg | — |